Sign up to save your podcasts
Or
Share ASH 2025
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASH 2025
ASH 2025 Highlights:
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
View all episodes
By John Bossaer
4.9
184184 ratings
ASH 2025 Highlights:
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
More shows like OncoPharm
View all
Planet Money
30,666 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
496 Listeners
White Coat Investor Podcast
2,438 Listeners
The Curbsiders Internal Medicine Podcast
3,351 Listeners
Core IM | Internal Medicine Podcast
1,147 Listeners
The ONS Podcast
206 Listeners
ASCO Guidelines
44 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
Home Cooking
4,869 Listeners
The Curious Clinicians
374 Listeners
Ninja Nerd
316 Listeners
Two Onc Docs
192 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
44 Listeners
WolverHeme Happy Hour
31 Listeners